Lv11
40 积分 2023-10-17 加入
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer
3小时前
已完结
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
11个月前
已完结
Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel
1年前
已完结
皖公网安备34019202002308
